Amendment to Drugs Rules, 1945

Background

The Central Government has amended the Drugs Rules, 1945 to bring Cell/Stem Cell-derived Products, Gene Therapeutic Products and Xenografts under the Centrally Licence Approving Authority (CLAA) framework. The amendment seeks to ensure uniform regulation, patient safety and responsible innovation in advanced healthcare.

Drugs Rules, 1945

The Drugs Rules, 1945 were framed under the Drugs and Cosmetics Act, 1940 to regulate the manufacture, import, sale, distribution and licensing of drugs and cosmetics in India. They prescribe standards for manufacturing, testing, storage, labelling and quality control, while defining the roles of Central and State Licensing Authorities.

What Has Changed?

The amendment expands the CLAA framework to include advanced biological and regenerative therapies. Cell or Stem Cell-derived Products include therapies developed from living cells or stem cells, such as stem-cell therapies and CAR-T cell therapy. Gene Therapeutic Products treat diseases by repairing, replacing or modifying genetic material, while Xenografts involve the transplantation of animal-derived tissues or organs into humans.

CLAA Framework

Under the expanded CLAA mechanism, these advanced products will be subject to joint regulation by Central and State Licensing Authorities. This is intended to establish uniform standards for quality, safety and efficacy, along with stronger licensing, inspection, scientific evaluation and post-approval monitoring.

Why Was the Amendment Needed?

Advanced therapies involve living cells, genetic material and animal tissues, making their manufacturing and safety assessment more complex than conventional medicines. The growing use of CAR-T therapy, stem-cell therapy and gene-based treatments therefore requires specialised regulatory oversight. A common framework also helps prevent variations in regulatory standards across States.

Significance

The amendment strengthens patient safety through more rigorous scientific assessment and regulatory scrutiny. It promotes uniform regulatory standards across India, while providing a clearer pathway for the adoption of innovative therapies.

A predictable regulatory framework can also encourage research, biotechnology investment and pharmaceutical innovation. At the same time, stronger oversight can facilitate safer access to advanced treatments for cancers, genetic disorders and other complex diseases, while improving public confidence in emerging medical technologies.